Stocklytics Platform
BFRI
Biofrontera
BFRIW5
$0.06arrow_drop_down1.69%-$0.00
Penny Stock
BFRI
BFRIW5

$0.06

arrow_drop_down1.69%

Performance History

Chart placeholder
Key Stats
Open$0.05
Prev. Close$0.06
EPS-1.29
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$0.00
PE Ratio-
LOWHIGH
Day Range0.05
0.09
52 Week Range0.00
0.20
Ratios
Revenue-
EPS-1.29

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About Biofrontera (BFRIW)

Biofrontera Inc. (BFRIW) is a biopharmaceutical company that specializes in the development and commercialization of innovative therapies for the treatment of dermatological conditions. The company is headquartered in Leverkusen, Germany, and has a global presence with subsidiaries in the United States and Europe. Biofrontera's primary focus is on the development of pharmaceuticals and medical devices for the treatment of skin cancer and other skin diseases.
The stock price history of Biofrontera Inc. (BFRIW) is a subject of interest for many investors and analysts. Over the years, the stock price has shown volatility and fluctuations, influenced by various factors such as market conditions, regulatory approvals, clinical trial results, and investor sentiment. It is important for investors to analyze the historical performance and trends of the stock to make informed investment decisions.
Sector
Industry
CEO
Headquarters
Employees
0
Exchange
NASDAQ
add Biofrontera to watchlist

Keep an eye on Biofrontera

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Biofrontera's (BFRIW) price per share?

The current price per share for Biofrontera (BFRIW) is $0.06. The stock has seen a price change of -$0 recently, indicating a -1.69% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Biofrontera (BFRIW)?

For Biofrontera (BFRIW), the 52-week high is $0.2, which is 220.81% from the current price. The 52-week low is $0, the current price is 1.18K% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Biofrontera (BFRIW) a growth stock?

Biofrontera (BFRIW) has shown an average price growth of -4.13% over the past three years. It has received a score of 0 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Biofrontera as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Biofrontera (BFRIW) stock price performance year to date (YTD)?

As of the latest data, Biofrontera (BFRIW) has a year-to-date price change of 539%. Over the past month, the stock has experienced a price change of 113%. Over the past six months, the figure is 21.71%.
help

Is Biofrontera (BFRIW) a profitable company?

Biofrontera (BFRIW) has a net income of -$20.13M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 48.8% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -64.69% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 18.82%, providing insight into the company's sales performance and growth. The gross profit is $16.63M. Operating income is noted at -$22.68M. Furthermore, the EBITDA is -$18.32M.
help

What is the market capitalization of Biofrontera (BFRIW)?

Biofrontera (BFRIW) has a market capitalization of $0. The average daily trading volume is 0.08, indicating the stock's liquidity and investor engagement.

News

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update
BIOFRONTERA INC.
AMELUZ®
RHODOLED XL
SBCC
ACTINIC KERATOSIS
Nov 13, 2024

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp
PRESS RELEASES
Jun 24, 2024

Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

Biofrontera Inc. Announces Voting Results from 2022 Annual Meeting of Stockholders
PRESS RELEASES
Dec 16, 2022

Biofrontera Inc. Announces Voting Results from 2022 Annual Meeting of Stockholders

Biofrontera Inc. to Participate in Benchmark’s 11th Annual Discovery One-on-One Investor Conference
PRESS RELEASES
Nov 30, 2022

Biofrontera Inc. to Participate in Benchmark’s 11th Annual Discovery One-on-One Investor Conference

BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON WEDNESDAY, NOVEMBER 30, MONDAY, DECEMBER 5, FRIDAY, DECEMBER 9, AND MONDAY, DECEMBER 19 2022
PRESS RELEASES
Nov 28, 2022

BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON WEDNESDAY, NOVEMBER 30, MONDAY, DECEMBER 5, FRIDAY, DECEMBER 9, AND MONDAY, DECEMBER 19 2022

Biofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business Update
PRESS RELEASES
Nov 14, 2022

Biofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business Update

Take Your Investments to a Whole New Level